The molecular biology of endometrial adenocarcinoma

Clinical Obstetrics and Gynecology

Volumn 39, Issue 3, 1996, Pages 707-715

  Baker, Vicki V ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CARCINOGENESIS; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; ONCOGENE NEU; ONCOGENE RAS; REVIEW;

ADENOCARCINOMA; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; GROWTH SUBSTANCES; HUMANS; MUTATION; PROTO-ONCOGENES;

EID: 0029743239     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199609000-00018     Document Type: Review

References (55)

1. Shah MK, et al. Cytogenetic and FISH analysis of endometrial carcinoma. Cancer Genet Cytogenet. 1994;73:1420-1426.
2. Milatovich A, Heerema NA, Palmer CG. Cytogenetic studies of endometrial malignancies. Cancer Genet Cytogenet. 1990;46:41-53.
3. Jones MH, Koi S, Fujimoto I, et al. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p,9q,10q and 17p. Genes Chromosomes Cancer. 1994;9:119-123.
4. Fujino T, Risinger JL, Collins NK, et al. Allelotype of endometrial carcinoma. Cancer Res. 1994;54:294-298.
5. Stancel GM, Baker VV, Hyder SM, et al. Oncogene and uterine function. In: Milligan SR, ed. Oxford Reviews of Reproductive Biology. 1993;15:1-42.
6. Boehm KD, Daimon M, Gorodeski IG, et al. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissue. Mol Reprod Develop. 1990;27:93-101.
7. Fager G, Hansson GK, Ottosson P, et al. Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. Exp Cell Res. 1988;176:319-355.
8. Brigstock DR. Growth factors in the uterus: steroidal regulation and biological actions. Ballieres Clin Endocrinol Metab. 1991;5:791-808.
9. Cordon-Cardo C, Vlodavsky I, Hainovitz-Friedman A, et al. Expression of basic fibroblast growth factor in normal human tissue. Lab Invest. 1990;63:832-40.
10. Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: Implications for the neovascularization of normal and neopiastic endometrium. J Cell Physiol. 1988;137:593-597.
11. Smith K, LeJeune S, Harris AH, et al. Epidermal growth factor receptor in human uterine tissues. Human Reprod. 1991;6:619-622.
12. Chegini N, Rao CV, Wakim N, Sanfilippo J. Binding of 125 I-Epidermal growth factor in human uterus. Cell Tissue Res. 1986;246:543-548.
13. Mukku VR, Stancel GM. Regulation of uterine epidermal growth factor receptors by estrogen. J Biol Chem. 1985;260:9820-9824.
14. Brumm C, Riviere A, Wilckens C, et al. Immunohistochemical investigation and northern blot analysis of c-erbB-2 expression in normal, premalignant, and malignant tissues of the corpus and cervix uteri. Virchows Arch A Pathol Anat Histopathol 1990;417:477-484.
15. Kacinski BM, Carter D, Mittal K, et al. High level of expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radial Oncol Biol Phys. 1988;15:823-829.
16. Baiocchi G, Kavanagh JJ, Talpaz M, et al. Expression of the macrophage colony stimulating factor and its receptor in gynecologic malignancies. Cancer. 1991;67:990-996.
17. Filderman AE, Bruckner A, Kacinski B, et al. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor positive carcinoma cell lines. Cancer Res. 1992;52:3661-3666.
18. Reynolds RK, Talavera F, Roberts JA, et al. Characterization of epidermal growth factor receptor in normal and neopiastic human endometrium. Cancer. 1990;66:1967-1974.
19. Borst MP, Baker VV, Dixon D, et al. Oncogene alterations in endometrial carcinoma. Gynecol Oncol. 1990;38:364-366.
20. Sasano H, Comoford J, Wilkinson DS, et al. Serous papillary adenocarcinoma of the endometrium; protooncogene amplification, flow cytometry, estrogen and progesterone receptors and immunohistochemical analysis. Cancer. 1990;65:1545.
21. Berchuck A, Rodriguez G, Kinney Rb, et al. Overexpression of HER-2/neu is associated with advanced stage disease. Am J Obstet Gynecol. 1991;164:15-21.
22. Sato S, Ito K, Ozawa N, et al. Expression of c-myc, epidermal growth factor receptor and c-erbB2 in human endometrial carcinoma and cervical adenocarcinoma. Tokohu J Exp Med. 1991;165:137.
23. Bigsby RM, Li AX, Bomalaski J, et al. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor and steroid receptor expression in normal and malignant endometrium. Gynecol Oncol. 1992;79:95.
24. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992;47:179.
25. Sato S. Evaluation of the degree of biological behavior in endometrial hyperplasia and endometrial carcinoma: an investigation of proliferative activity, oncogene and extra-cellular matrix. Acta Obstet Gynecol Jpn. 1993;45:776.
26. McCann AH, et al. Prognostic significance of c-erbB2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51:3296.
27. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in neoplasms of the human female genital tract. Cancer Res. 1990;50:6139-6145.
28. Nasim S, Mizuuchi H, Garrett CT. Direct DNA sequencing of polymerase chain reaction amplified fragments in evaluation of neoplastic disease. Proceedings of the Annual Meeting of the American Association of Cancer Research. 1990;31:328.
29. Sato S, Ito K, Ozawa N, et al. Analysis of point mutations at codon 12 of K-ras in human endometrial carcinoma and cervical adenocarcinoma by dot blot hybridization and polymerase chain reaction. Tohoku J Exp Med. 1991;165:131.
30. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51:5308-5314.
31. Fujimoto I, Shimizu Y, Hirai Y, et al. Study of ras oncogene activation in endometrial carcinoma. Gynecol Oncol. 1993;48:196.
32. Mizuuchi H, Nasim S, Kudo R, et al. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res. 1992;52:2777-2781.
33. Yaginuma Y, Fujita M, Saitoh S, et al. Immunohistochemical analysis of ras oncogene product p21 in human endometrial carcinoma. Acta Histochem. 1993;95:23-29.
34. Monk BJ, Chapman JA, Johnson GA, et al. Correlation of c-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol. 1994;171:1193-1198.
35. Naito M, Satake M, Sakai E, et al. Detection of p53 gene in human ovarian and endometrial cancers by polymerase chain reaction single strand conformation polymorphism analysis. Jpn J Cancer Res. 1992;83:1030-1036.
36. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res. 1991;51:5632-5636.
37. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutations of p53 in endometrial carcinoma. Cancer Res. 1992;52:1622-1627).
38. Risinger JE, Dent GA, Ignar-Trowbridge D, et al. p53 gene mutations in human endometrial carcinoma. Mol Carcinogen. 1992;5:250-253.
39. Bur ME, Perlman C, Edelmann L, et al. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol. 1992;98:81-87.
40. Jiko K, Sasano H, Ito K, et al. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res. 1993;13:305.
41. Ito K, Watanabe K, Nasim S, et al. Prognostic signficance of p53 over-expression in endometrial cancer. Cancer Res. 1994;54:4667-4670.
42. Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer. 1994;73:1686-1692.
43. Pisani AL, Barbuto DA, Chen D, et al. HER-2/neu, p53 and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol. 1995;85:729-734.
44. Schneider J, et al. P-glycoprotein, HER-2/ neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst. 1994;86:850-855.
45. King SA, Adas AA, LiVolsi VA, et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer. 1995;75:2700-2705.
46. Malfetano J, Figge HL, Ross JS. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer. 1994;73:1686-1692.
47. Sasano H, et al. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer. 1990;66:2150-2154.
48. Enomoto T, Fujita M, Inoue M, et al. Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial adenocarcinoma. Mol Carcinogen. 1993;8:132-137.
49. Sekeris CE. Hormonal steroids act as tumor promoters by modulating oncogene expression. J Cane Res Clin Oncol. 1991;117:96-101.
50. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras proto-oncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53:1906-1910.
51. Bai MK, Costopoulos JS, Chrisloforidou BP, Papdimitriou CS. Immunohistochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology. 1994;51:314-319.
52. Bulletti C, et al. Basement membrane in human endometrium: possible role of proteolytic enzymes in developing hyperplasia and carcinoma. Ann N Y Acad Sci. 1991;622:376-382.
53. Gold LI, Saxena B, Mittal KR, et al. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res. 1994;54:2347-2358.
54. Sasano H, et al. Tenascin expression in normal and abnormal human endometrium. Mod Pathol. 1993;6:323-326.
55. Teni TR, et al. Inhibin (10.7 k D prostatic peptide) in normal, hyperplastic, and malignant endometria: an immunohistochemical study. J Pathol. 1992;168:35-40.